Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.
Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.
Caribou Biosciences is exploring strategic alternatives and implementing a restructuring plan that includes discontinuing its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. The company is conducting a substantial workforce reduction and expects to incur restructuring charges between $15 million and $19 million, primarily for severance and clinical trial wind-down costs.